Menu Back toThe-Impact-of-Cell-and-Gene-Therapy-on-the-Payer-System

DIA 2018 Global Annual Meeting

The Impact of Cell and Gene Therapy on the Payer System

    Session Chair(s)
      Marianne  Hamilton Lopez, PhD, MPA

      Marianne Hamilton Lopez, PhD, MPA

      • Research Director, Value-Based Payment Reform
      • Duke-Margolis Center For Health Policy, United States
    to be developed
    Learning Objective : In this presentation participants should expect to garner a basic understanding of Cell and Gene Therapies and the difference from small and large molecule therapeutics. Participants will also decipher how those differences impact models for reimbursement and payment. Further, participants will evaluate the influence partnerships will have in developing this payer system.
      Dan  Tierno, MA, MBA

      Cell and Gene Therapy Development and the Impact on the Payer System

      Dan Tierno, MA, MBA

      • Strategic Implementation Manager
      • Bayer, United States